Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review)

Sethi JK and Vidal-Puig AJ: Thematic review series: Adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 48:1253–1262. 2007. View Article : Google Scholar : PubMed/NCBI

Luo L and Liu M: Adipose tissue in control of metabolism. J Endocrinol. 231:R77–R99. 2016. View Article : Google Scholar : PubMed/NCBI

Jung UJ and Choi MS: Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 15:6184–6223. 2014. View Article : Google Scholar : PubMed/NCBI

Curat CA, Miranville A, Sengenè C, Diehl M, Tonus C, Busse R and Bouloumié A: From blood monocytes to adipose tissue-resident macrophages: Induction of diapedesis by human mature adipocytes. Diabetes. 53:1285–1292. 2004. View Article : Google Scholar : PubMed/NCBI

Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, et al: Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 360:1509–1517. 2009. View Article : Google Scholar : PubMed/NCBI

Nauli AM and Matin S: Why do men accumulate abdominal visceral fat? Front Physiol. 10:14862019. View Article : Google Scholar : PubMed/NCBI

Kahn CR, Wang G and Lee KY: Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 129:3990–4000. 2019. View Article : Google Scholar : PubMed/NCBI

Blüher M: Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 117:241–250. 2009. View Article : Google Scholar : PubMed/NCBI

Tan CY and Vidal-Puig A: Adipose tissue expandability: The metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans. 36:935–940. 2008. View Article : Google Scholar : PubMed/NCBI

Sebo ZL and Rodeheffer MS: Assembling the adipose organ: Adipocyte lineage segragation and adipogenesis in vivo. Development. 146:dev1720982019. View Article : Google Scholar : PubMed/NCBI

Lafontan M and Langin D: Lipolysis and lipid modilization in human adipose tissue. Prog Lipid Res. 48:275–297. 2009. View Article : Google Scholar : PubMed/NCBI

Frayn KN: Adipose tissue as a buffer for daily lipid flux. Diabetologia. 45:1201–1210. 2002. View Article : Google Scholar : PubMed/NCBI

Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS and Obin MS: Adipocyte death defines macrophage location and function in adipose tissue of obese mice and humans. J Lipid Res. 46:2347–2355. 2005. View Article : Google Scholar : PubMed/NCBI

Ellulu MS, Patimah I, Khazaai H, Rahmat A and Abed Y: Obesity and inflammation: The linking mechanism and the complications. Arch Med Sci. 13:851–863. 2017. View Article : Google Scholar : PubMed/NCBI

Hotamisligil GS: Inflammation and metabolic disorders. Nature. 444:860–867. 2006. View Article : Google Scholar : PubMed/NCBI

Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 115:911–919. 2005. View Article : Google Scholar : PubMed/NCBI

Weir CB and Jan A: BMI classification percentile and cut off points. StatPearls Treasure Island, FL: StatPearls Publishing; 2020

Marcadenti A and de Abreu-Silva EO: Different adipose tissue depots: Metabolic implications and effects of surgical removal. Endocrinol Nutr. 62:458–464. 2015. View Article : Google Scholar : PubMed/NCBI

Fuster JJ, Ouchi N, Gokce N and Walsh K: Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 118:1786–1807. 2016. View Article : Google Scholar : PubMed/NCBI

Osborn O and Olefsky JM: The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 18:363–374. 2012. View Article : Google Scholar : PubMed/NCBI

Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A and Smith U: Insulin resistance and impaired adipogenesis. Trends Endocrinol Metab. 26:193–200. 2015. View Article : Google Scholar : PubMed/NCBI

Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN and Ross R: Visceral fat in an independent predictor of all-cause mortality in men. Obesity (Silver Spring). 14:336–341. 2006. View Article : Google Scholar : PubMed/NCBI

Klein J, Permana PA, Owecki M, Chaldakov GN, Böhm M, Hausman G, Lapière CM, Atanassova P, Sowiński J, Fasshauer M, et al: What are subcutaneous adipocytes really good for? Exp Dermatol. 16:45–70. 2007. View Article : Google Scholar : PubMed/NCBI

Cameron AJ, Magliano DJ and Soderberg S: A systemic review of the impact of including both waist and hip circumference in risk models for cardiovascular diseases, diabetes and mortality. Obes Rev. 14:86–94. 2013. View Article : Google Scholar : PubMed/NCBI

Koster A, Murphy RA, Eiriksdottir G, Aspelund T, Sigurdsson S, Lang TF, Gudnason V, Launer LJ and Harris TB: Fat distribution and mortality: The AGES-Reykjavik study. Obesity (Silver Spring). 23:893–897. 2015. View Article : Google Scholar : PubMed/NCBI

Arner P, Andersson DP, Thörne A, Wirén M, Hoffstedt J, Näskybd E, Thorell A and Rydén M: Variations in the size of the major omentum are primarily determined by fat cell number. J Clin Endocrinol Metab. 98:E897–E901. 2013. View Article : Google Scholar : PubMed/NCBI

Chait A and den Hartigh LJ: Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 25:222020. View Article : Google Scholar : PubMed/NCBI

James WP: Assessing obesity: Are ethnic differences in body mass index and waist classification criteria justified? Obes Rev. 6:179–181. 2005. View Article : Google Scholar : PubMed/NCBI

James WP, Rigby N and Leach R: Obesity and the metabolic syndrome: The stress on society. Ann N Y Acad Sci. 1083:1–10. 2006. View Article : Google Scholar : PubMed/NCBI

El-Sayed AM, Scarborough P and Galea S: Ethnic inequalities in obesity among children and adults in the UK: A systematic review of the literature. Obes Rev. 12:e516–e534. 2011. View Article : Google Scholar : PubMed/NCBI

Barnett AH, Dixon AN, Bellary S, Hanif MW, O'Hare JP, Raymond NT and Kumar S: Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia. 49:2234–2246. 2006. View Article : Google Scholar : PubMed/NCBI

Misra A and Khurana L: Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int J Obes (Lond). 35:167–187. 2011. View Article : Google Scholar : PubMed/NCBI

Pi-Sunyer X: The medical risks of obesity. Postgrad Med. 121:21–33. 2009. View Article : Google Scholar : PubMed/NCBI

Kyrou I, Randeva HS, Tsigos C, Kaltsas G, Weickert MO, Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al: Clinical problems caused by obesity. Endotext [Internet] South Dartmouth (MA): MDText.com, Inc; 2018

Khanna D, Khanna S, Khanna P, Kahar P and Patel BM: Obesity: A chronic low-grade inflammation and its markers. Cureus. 14:e227112022.PubMed/NCBI

Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, Möhlig M, Pfeiffer AFH and Spranger J: Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 54:2712–2719. 2005. View Article : Google Scholar : PubMed/NCBI

Hotamisligil GS, Shargill NS and Spiegelman BM: Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science. 259:87–91. 1993. View Article : Google Scholar : PubMed/NCBI

Mohlig M, Weickert MO, Ghadamgadai E, Machlitt A, Pfüller B, Arafat AM, Pfeiffer AFH and Schöfl C: Adipocyte fatty acid-binding protein is associated with marker of obesity, but is an unlikely link between obesity, insulin resistance and hyperandrogenism in polycystic ovary syndrome women. Eur J Endocrinol. 157:195–200. 2007. View Article : Google Scholar : PubMed/NCBI

Fonseca-Alaniz MH, Takada J, Alonso-Vale MI and Lima FB: Adipose tissue as an endocrine organ: From theory to practice. J Pediatr. 83:192–203. 2007. View Article : Google Scholar : PubMed/NCBI

Maury E and Brichard SM: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 314:1–16. 2010. View Article : Google Scholar : PubMed/NCBI

Gregor MF and Hotamilsigil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol. 29:415–445. 2011. View Article : Google Scholar : PubMed/NCBI

Weickert MO, Hodges P, Tan BK and Randeva HS: Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: The role of metformin. Minerva Endocrinol. 37:25–40. 2012.PubMed/NCBI

Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N and Lehnert H: Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 33:812–841. 2012. View Article : Google Scholar : PubMed/NCBI

Makki K, Froguel P and Wolowczuk I: Adipose tissue in obesity-related inflammation and insulin resistance. Cells, cytokines and chemokines. ISRN Inflamm. 2013:1392392013. View Article : Google Scholar : PubMed/NCBI

Sivakumar K, Bari MF, Adaikalakoteswari A, Guller S, Weickert MO, Randeva HS, Grammatopoulos DK, Bastie CC and Vatish M: Elevated fetal adispin/acylation-stimulating protein (ASP) in obese pregnancy: Novel placental secretion via Hofbauer cells. J Clin Endocrinol Metab. 98:4113–4122. 2013. View Article : Google Scholar : PubMed/NCBI

von Loeffelholz C, Mohlig M, Arafat AM, Isken F, Spranger J, Mai K, Randeva HS, Pfeiffer AFH and Weickert MO: Circulation vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol. 162:507–513. 2013. View Article : Google Scholar : PubMed/NCBI

Elmasry SA, Al-Azzawi MA, Ghoneim AH, Nasr MY and AboZaid MMN: Role of oxidant-antioxidant imbalance in the pathogenesis of chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 64:813–820. 2015. View Article : Google Scholar

Marseglia L, Manti S, D'Angelo G, Nicotera A, Parisi E, Di Rosa G, Gitto E and Arrigo T: Oxidative stress in obesity: A critical component in human diseases. Int J Mol Sci. 16:378–400. 2015. View Article : Google Scholar

Reilly SM and Saltiel AR: Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 13:633–643. 2017. View Article : Google Scholar : PubMed/NCBI

Rheinheimer J, de Souza BM, Cardoso NS, Bauer AC and Crispim D: Current role of the NLRP3 inflammasome on obesity and insulin resistance: A systematic review. Metabolism. 74:1–9. 2017. View Article : Google Scholar : PubMed/NCBI

Deshmane SL, Kremley S, Amini S and Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res. 29:313–326. 2009. View Article : Google Scholar : PubMed/NCBI

Taylor EB: The complex role of adipokines in obesity, inflammation and autoimmunity. Clin Sci (Lond). 135:731–752. 2021. View Article : Google Scholar : PubMed/NCBI

Matsushima K, Larsen CG, DuBois GC and Oppenheim JJ: Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myolomonocytic cell line. J Exp Med. 169:1485–1490. 1989. View Article : Google Scholar : PubMed/NCBI

Rollins BJ: Chemokines. Blood. 90:909–928. 1997. View Article : Google Scholar : PubMed/NCBI

Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K and Kasuga M: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 116:1494–1505. 2006. View Article : Google Scholar : PubMed/NCBI

Singh S, Anshita D and Ravichandiran V: MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 101((PtB)): 1075982021. View Article : Google Scholar : PubMed/NCBI

Dietze-Schroeder D, Sell H, Uhlig M, Koener M and Eckel J: Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes. 54:2003–2011. 2005. View Article : Google Scholar : PubMed/NCBI

Christiansen T, Richelsen B and Bruun JM: Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond). 29:146–150. 2005. View Article : Google Scholar : PubMed/NCBI

Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, et al: Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 54:2277–2286. 2005. View Article : Google Scholar : PubMed/NCBI

Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, Constantio F, Ruotolo G, Luzi L and Perseglin G: Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: Impact on cardiovascular mortality. Diabetes Care. 26:2883–2889. 2003. View Article : Google Scholar : PubMed/NCBI

Simeoni E, Hoffman MM, Winkelman BR, Ruiz J, Fleury S, Boehm BO, März W and Vassalli G: Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus. Diabetologia. 47:1574–1580. 2004. View Article : Google Scholar : PubMed/NCBI

Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C, Illig T, Martin S and Kolb H: Chemokines as risk factors for type 2 diabetes: Results from the MONICA/KORA Augsburg study, 1984–2002. Diabetologia. 49:921–929. 2006. View Article : Google Scholar : PubMed/NCBI

Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Rrickson KL and Yu R: Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond). 30:1347–1355. 2006. View Article : Google Scholar : PubMed/NCBI

Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerpach AC, Clement N, Moes S, Colombi M, Meier JA, et al: Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 128:1538–1550. 2018. View Article : Google Scholar : PubMed/NCBI

Zhu B, Guo X, Xu H, Jiang B, Li H, Wang Y, Yin O, Zhou T, Cai JJ, Glaser S, et al: Adipose tissue inflammation and systemic insulin resistance in mice with diet-induced obesity is possibly associated with disruption of PFKFB3 in hematopoietic cells. Lab Invest. 101:328–340. 2021. View Article : Google Scholar : PubMed/NCBI

Ylä-Herttuala S, Lipton A, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL and Steinberg D: Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA. 88:5252–5256. 1991. View Article : Google Scholar : PubMed/NCBI

Arakelyan A, Petrkova J, Hermanova Z, Boyajyan A, Lukl J and Petrek M: Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardiac infarction. Mediators Inflamm. 14:175–179. 2005. View Article : Google Scholar : PubMed/NCBI

Sukumar D, Partridge C, Wang X and Shapses SA: The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab. 296:1852–1858. 2011. View Article : Google Scholar : PubMed/NCBI

Takeya M, Yoshimura T, Leonard EJ and Takahashi K: Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 24:534–539. 1993. View Article : Google Scholar : PubMed/NCBI

Gu L, Οkada Y, Clinton SK, Gerard C, Sukhova GK, Libby P and Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-defined mice. Mol Cell. 2:275–281. 1998. View Article : Google Scholar : PubMed/NCBI

Boring M, Gosling J, Cleary M and Charo IF: Decreased lesion in CCR2-/- mice reveals a role for chemokines in the initation of atherosclerosis. Nature. 394:894–897. 1998. View Article : Google Scholar : PubMed/NCBI

Deng Y and Scherer PE: Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 1212:E1–E19. 2010. View Article : Google Scholar : PubMed/NCBI

Dutheil F, Gordon BA, Naughton G, Crendal E, Courteix D, Chaplais E, Thivel D, Lac G and Benson AC: Cardiovascular risk of adipokines: A review. J Inter Med Res. 46:2082–2095. 2018. View Article : Google Scholar : PubMed/NCBI

Szumilas K, Szumilas P, Słuczanowska-Głąbowsk S, Zgutka K and Pawlik A: Role of adiponectin in the pathogenesis of Rheumatoid arthritis. Int J Mol Sci. 21:82652020. View Article : Google Scholar : PubMed/NCBI

Adolph TE, Grander C, Grabherr F and Tilg H: Adipokines and non-alcoholic fatty liver disease: Multiple interactions. Int J Mol Sci. 18:16492017. View Article : Google Scholar : PubMed/NCBI

Neumann UH, Chen S, Tam YY, Baker RK, Covey SD, Dullis PP and Kieffer TJ: IGFBP2 is neither sufficient nor necessary for the physiological actions of leptin on glucose homeostasis in male ob/ob mice. Endocrinology. 155:716–725. 2014. View Article : Google Scholar : PubMed/NCBI

Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M and Mrugacz M: Adipokines in obesity. Potential lind to metabolic disorders and chronic complications. Int J Mol Sci. 21:35702020. View Article : Google Scholar : PubMed/NCBI

Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, et al: Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 109:2046–2049. 2004. View Article : Google Scholar : PubMed/NCBI

Quedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, Scalia R and Goldstein BJ: Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: Evidence for involvement of a cAMP signaling pathway. Diabetes. 55:1840–1846. 2006. View Article : Google Scholar : PubMed/NCBI

Yuan F, Li YN, Liu YH, Yi B, Tian JW and Liu FY: Adiponectin inhibits the generation of reactive oxygen species induced by high glucose and promotes endothelial NO synthase formation in human mesangial cells. Mol Med Rep. 6:449–453. 2012. View Article : Google Scholar : PubMed/NCBI

Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M and Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 114:1752–1761. 2004. View Article : Google Scholar : PubMed/NCBI

Castro JR, Grune T and Speckmann B: The two faces of reactive oxygen species (ROS) in adipocyte function and dysfunction. Biol Chem. 397:709–724. 2016. View Article : Google Scholar : PubMed/NCBI

Fujita K, Nishizawa H, Funahashi T, Shimomura I and Shimabukuro M: Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circulation. 70:1437–1442. 2006. View Article : Google Scholar : PubMed/NCBI

Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M and Sugimoto T: Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol. 8:512007. View Article : Google Scholar : PubMed/NCBI

Xie C and Chen Q: Adipokines: New therapeutic target for osteoarthritis? Curr Reumatol Rep. 21:712020.

Gamberi Τ, Μagherini F, Modesti A and Fiaschi T: Adiponectin signaling pathways in liver diseases. Biomedicines. 6:522018. View Article : Google Scholar : PubMed/NCBI

Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, et al: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 103:1057–1063. 2001. View Article : Google Scholar : PubMed/NCBI

Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, et al: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem. 277:37487–37491. 2002. View Article : Google Scholar : PubMed/NCBI

Kadowaki T and Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev. 26:439–451. 2005. View Article : Google Scholar : PubMed/NCBI

Zha N, Wu X and Gao P: Adiponectin and its receptors in diabetic kidney disease: Molecular mechanisms and clinical potential. Endocrinol. 158:2022–2034. 2017. View Article : Google Scholar

Alnaggar ARLR, Sayed M, El-Deena KE, Gomma M and Hamed Y: Evaluation of serum adiponectin levels in diabetic nephropathy. Diabetes Metab Syndr. 13:128–131. 2019. View Article : Google Scholar : PubMed/NCBI

Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ and Scalia R: Adiponectin deficiency increases leukocyte-endothelium interactions via up-regulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 117:1718–1761. 2007. View Article : Google Scholar : PubMed/NCBI

Abella V, Scotece M, Conde J, López V, Lazzaro V, Pino J, Gómez-Rein O and Gualillo O: Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res. 2014:3437462014. View Article : Google Scholar : PubMed/NCBI

Stefan N and Stumvoll M: Adiponectin-its role in metabolism and beyond. Horm Metab Res. 34:469–474. 2002. View Article : Google Scholar : PubMed/NCBI

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE and Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86:1930–1935. 2001. View Article : Google Scholar : PubMed/NCBI

Arita Y, Kihara S, Ouchi N, Takahashi M, Maed K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 257:79–83. 1999. View Article : Google Scholar : PubMed/NCBI

Scherer PE: Adipose tissue. From lipid storage compartment to endocrine organ. Diabetes. 55:1537–1545. 2006. View Article : Google Scholar : PubMed/NCBI

Trujillo ME and Scherer PE: Adipose tissue-derived factors: Impact on health and disease. Endocr Rev. 27:762–778. 2006. View Article : Google Scholar : PubMed/NCBI

Oh DK, Ciaraldi T and Henry RR: Adiponectin in health and disease. Diabetes Obes Metab. 9:282–289. 2007. View Article : Google Scholar : PubMed/NCBI

Li S, Shin HJ, Ding EL and van Dam RM: Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 302:179–188. 2009. View Article : Google Scholar : PubMed/NCBI

Li C, Cheng H, Adhikari BK, Wang S, Yang N, Liu W, Sun J and Wang Y: The role of apelin-APJ system in diabetes and obesity. Front Endocrinol (Lausanne). 2022:132022.

Al-Mansoori L, Al-Jaber H, Price MS and Elrayess MA: Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation. 45:31–44. 2022. View Article : Google Scholar : PubMed/NCBI

Vykoukal D and Davies MG: Vascular biology of metabolic syndrome. J Vasc Surg. 54:819–831. 2011. View Article : Google Scholar : PubMed/NCBI

Than A, He HL, Chua SH, Xu D, Sun L, Leow MKS and Chen P: Apelin enhances brown adipogenesis and browning of white adipocytes. J Biol Chem. 290:1469–14691. 2015. View Article : Google Scholar

Yamamoto T, Habata Y, Matsumoto Y, Yasuhara Y, Hashimoto T, Hamajyo H, Anayama H, Fujii R, Fuse H, Shintani Y and Mori M: Apelin-transgenic mice exhibit a resistance against diet-induced obesity by increasing vascular mass and mitochondrial biogenesis in skeletal muscle. Biochim Biophys Acta. 1810:853–862. 2011. View Article : Google Scholar : PubMed/NCBI

Mughal A and O'Rourke ST: Vascular effects on apelin: Mechanisms and therapeutic potential. Pharmacol Ther. 190:139–147. 2018. View Article : Google Scholar : PubMed/NCBI

Yamazaki S, Sekiguchi A, Uchiyama A, Fujiwara C, Inoue Y, Yokoyama Y, Ogino S, Torii R, Hosoi M, Akai R, et al: Apelin/APJ signaling suppresses the pressure ulcer formation in cutaneous ischemia-perfusion injury mouse model. Sci Rep. 10:13492020. View Article : Google Scholar : PubMed/NCBI

Attané C, Foussal C, Gonidec SL, Benani A, Daviaud D, Wanecq E, Guzmán-Ruiz R, Dray C, Bezaire V, Rancoule C, et al: Apelin treatment increases complete fatty acid oxidation, mitochondrial oxidative capacity and biogenesis in muscle of insulin-resistant mice. Diabetes. 61:310–320. 2012. View Article : Google Scholar : PubMed/NCBI

Lay SL, Simard G, Martinez MC and Andriantsitohaina R: Oxidative stress and metabolic pathologies: From an adipocentric point of view. Oxid Med Cell Longev. 2014:9085392014.PubMed/NCBI

Kim S, Kim S, Hwang AR, Choi HC, Lee JY and Woo CH: Apelin-13 inhibits methylglyoxal-induced unfolded protein responses and endothelial dysfuction via regulating AMPK pathway. Int J Mol Sci. 21:40692020. View Article : Google Scholar : PubMed/NCBI

Fibbi B, Marroncini G, Naldi L and Peri A: The Yin and Yang effects of the apelinergic system in oxidative stress. Int J Mol Sci. 24:47452023. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM: Positional cloning of the mouse obes gene and its human homologue. Nature. 372:425–432. 1994. View Article : Google Scholar : PubMed/NCBI

Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK and Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:543–546. 1995. View Article : Google Scholar : PubMed/NCBI

Caro JF, Sinha MK, Kolaczynski JW, Zhang PL and Considine RV: Leptin: The tale of an obesity gene. Diabetes. 45:1455–1462. 1996. View Article : Google Scholar : PubMed/NCBI

Fantuzzi G and Faggioni R: Leptin in the regulation of immunity, inflammation and haematopoiesis. J Leukoc Biol. 68:437–446. 2000. View Article : Google Scholar : PubMed/NCBI

Münzberg H and Morrison CD: Structure, production and signaling of leptin. Metabolism. 64:13–23. 2015. View Article : Google Scholar : PubMed/NCBI

Trayhurn P, Duncan JS, Hoggard N and Rayner DV: Regulation of leptin production: A dominant role for the sympathetic nervous system? Proc Nutr Soc. 57:413–419. 1998. View Article : Google Scholar : PubMed/NCBI

Dieguez C, Vazquez MJ, Romero A, Lopez M and Nogueiras R: Hypothalamic control of lipid metabolism: Focus on leptin, ghrelin and melanocortins. Neuroendocrinology. 94:1–11. 2011. View Article : Google Scholar : PubMed/NCBI

Morton GJ and Schwartz MW: Leptin and the central nervous system control of glucose metabolism. Physiol Rev. 91:389–411. 2011. View Article : Google Scholar : PubMed/NCBI

Sahu A: Leptin signaling in the hypothalamus: Emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol. 24:225–253. 2003. View Article : Google Scholar : PubMed/NCBI

Blaszczak AM, Jalilvand A and Hsueh WA: Adipocytes, innate immunity and obesity: A mini-review. Front Immunol. 12:6507682021. View Article : Google Scholar : PubMed/NCBI

Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, Gojobori T and Isenovic ER: Leptin and obesity: Role and clinical implication. Front Endocrinol (Lausanne). 12:5858872021. View Article : Google Scholar : PubMed/NCBI

Fahed G, Aoun L, Zerdan MB, Allam S, Zerdan MB, Bouferraa Y and Assi HI: Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci. 23:7862022. View Article : Google Scholar : PubMed/NCBI

van den Hoek AM, Teusink B, Voshol PJ, Havekes LM, Romijn JA and Piji H: Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. J Neuroendocrinol. 20:120–127. 2008. View Article : Google Scholar : PubMed/NCBI

Zhang H, Xie H, Zhao Q, Xie GQ, Wu XP, Liao EY and Luo XH: Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest. 33:707–711. 2010. View Article : Google Scholar : PubMed/NCBI

Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, et al: Pathophysiological role of leptin in obesity-related hypertension. J Clin Investig. 105:1243–1252. 2000. View Article : Google Scholar : PubMed/NCBI

Ferri C, Desideri G, Valenti M, Bellini C, Pasin M, Santucci A and De Mattia G: Early up-regulation of endothelial adhesion molecules in obese hypertensive men. Hypertension. 34:568–573. 1999. View Article : Google Scholar : PubMed/NCBI

Hukshorn CJ, Lindeman JH, Toet KH, Saris WH, Eilers PH, Westerterp-Plantenga MS and Kooistra T: Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab. 89:1773–1778. 2004. View Article : Google Scholar : PubMed/NCBI

Kim JE, Kim JS, Jo MJ, Cho E, Ahn SY, Kwon YJ and Ko GJ: The roles and associated mechanisms of adipokines in development of metabolic syndrome. Molecules. 27:3342022. View Article : Google Scholar : PubMed/NCBI

Romacho T, Valencia I, Ramos-González MR, Vallejo S, López-Esteban M, Lorenzo O, Cannata P, Romero A, Hipólito-Luengo AS, Gómez-Cerezo JF, et al: Visfatin/eNampt induces endothelial dysfunction in vivo: A role for toll-like receptor 4 and NLRP3 inflammasome. Sci Rep. 10:53862020. View Article : Google Scholar : PubMed/NCBI

Toussirot E: Mini review: The contribution of adipokines to joint inflammation in inflammatory rheumatic diseases. Front Endocrinol (Lausanne). 11:6065602020. View Article : Google Scholar : PubMed/NCBI

Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, Cienfuegos JA, Salvador J and Frühbeck G: Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis. 21:245–253. 2011.PubMed/NCBI

Chang YH, Chang DM, Lin KC, Shin SJ and Lee YJ: Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Metab Res Rev. 27:515–527. 2011. View Article : Google Scholar : PubMed/NCBI

Martos-Moreno GA, Kratzch J, Korner A, Barrios V, Hawkins F, Kiess W and Argente J: Serum visfatin and vispin levels in prepubertal childres: Effect of obesity and weitht loss after beharior modifications on their secretion and relationship with glucose metabolism. Int J Obes (Lond). 35:1355–1362. 2011. View Article : Google Scholar : PubMed/NCBI

Olszanecka-Glinianowicz M, Kocełak P, Nylec M, Chudek J and Zahorska-Markiewicz B: Circulating visfatin level and visfatin/insulin ration in obese women with metabolic syndrome. Arch Med Sci. 8:214–218. 2012. View Article : Google Scholar : PubMed/NCBI

de Luis DA, Aller R, Sagrado MG, Conde R, Izaola O and de la Fuente B: Serum visfatin levels and metabolic syndrome criteria in obese female subjects. Diabetes Metab Res Rev. 29:576–581. 2013. View Article : Google Scholar : PubMed/NCBI

Friebe D, Neef M, Kratzch J, Erbs S, Dittrich K, Garten A, Petzold-Qunque S, Blüher S, Reinehr T, Stumvoll M, et al: Leucocytes are a major source of circulating nicotinamide phorsphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 54:1200–1211. 2011. View Article : Google Scholar : PubMed/NCBI

Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, Jang HO, Yun Il, Kim KW, Kwon YG, et al: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κΒ activation in endothelial cells. Biochim Biophys Acta. 1783:886–895. 2008. View Article : Google Scholar : PubMed/NCBI

Patel SD, Rajala MW, Rossetti L, Scherer PE and Shapiro L: Disulfide-dependent multimeric assembly of resistin family hormones. Science. 304:1154–1158. 2004. View Article : Google Scholar : PubMed/NCBI

Oki K, Yamane K, Kamei N, Nojima H and Kohno N: Circulatin visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf). 67:796–800. 2007. View Article : Google Scholar : PubMed/NCBI

Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H and Tigl H: Visfatin an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 178:1748–1758. 2007. View Article : Google Scholar : PubMed/NCBI

Krysiak R, Handzlik-Orlik G and Okopien B: The role of adipokines in connective tissue diseases. Eur J Nutr. 51:513–528. 2012. View Article : Google Scholar : PubMed/NCBI

Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW and Kim HJ: Visfatin induces inflammation and insulin resistance via the NF-κΒ and STAT3 signaling pathways in hepatocytes. J Diabet Res. 2019:40216232019. View Article : Google Scholar : PubMed/NCBI

Francisco V, Sanz MJ, Real JT, Marques P, Capuozzo M, Eldjoudi DA and Gualillo O: Adipokines in non-alcoholic fatty liver disease: Are we on the road toward new biomarkers and therapeutic targets? Biology (Basel). 11:12372022.PubMed/NCBI

Oita RC, Ferdinando D, Wilson S, Bunce C and Mazzatti DJ: Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFκΒ-dependent manner. Pflugers Arch. 459:619–630. 2010. View Article : Google Scholar : PubMed/NCBI

Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, Lee S, Kim JY, Lee J, Yang HM, et al: Adenylyl cyclase-associated protein 1 (CAP1) is a receptor for human resistin and mediated inflammatory actions of human monocytes. Cell Metab. 19:484–497. 2014. View Article : Google Scholar : PubMed/NCBI

Li Y, Yang Q, Cai D, Guo H, Fang J, Cui H, Gou L, Deng J, Wang Z and Zuo Z: Resistin, a novel host defence peptide of innate immunity. Front Immunol. 12:6998072021. View Article : Google Scholar : PubMed/NCBI

Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K and Nagai R: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 314:415–419. 2004. View Article : Google Scholar : PubMed/NCBI

Bokarewa M, Nagaev I, Dahlberg L, Smith U and Tarkowski A: Resistin, an adipokine with potent proimflammatory properties. J Immunol. 174:5789–5795. 2005. View Article : Google Scholar : PubMed/NCBI

Agaev I, Bokarewa M, Tarkowski A and Smith U: Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One. 1:e312006. View Article : Google Scholar : PubMed/NCBI

Ebihara T, Matsumoto H, Matsubara T, Matsuura H, Hirose T, Shimizu K, Ogura H, Kang S, Tanaka T and Shimazu T: Adipocytokine profile reveals resistin forming a prognostic-related cytokine network in the acute phase of sepsis. Shock. 56:718–726. 2021. View Article : Google Scholar : PubMed/NCBI

Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E and Smith SR: Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metabol. 89:1844–1848. 2004. View Article : Google Scholar : PubMed/NCBI

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS and Lazar MA: The hormone resistin links obesity to diabetes. Nature. 409:307–312. 2001. View Article : Google Scholar : PubMed/NCBI

Vidal-Puig A and O'Rahilly S: Resistin: A new link between obesity and insulin resistance? Clin Endocrinol (Oxf). 55:437–438. 2001. View Article : Google Scholar : PubMed/NCBI

McTernan CL, McTernan PG, Harte AL, Levick PL, Barnet AH and Kumar S: Resistin, central obesity, and type 2 diabetes. Lancet. 359:46–47. 2002. View Article : Google Scholar : PubMed/NCBI

Wang H, Chu WS, Hemphill C and Elbein SC: Hunan resistin gene: Molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metabol. 87:2520–2524. 2002. View Article : Google Scholar : PubMed/NCBI

Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W, et al: The G/G genotype of resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 75:678–686. 2004. View Article : Google Scholar : PubMed/NCBI

Kielstein JT, Becker B, Graf S, Brabant G, Haller H and Fliser D: Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis. 42:62–66. 2003. View Article : Google Scholar : PubMed/NCBI

Patel L, Buckels AC, Kinghorn IJ, Mourdock PR, Holbrook JD, Plumpton C, Macphee CH and Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 300:472–476. 2003. View Article : Google Scholar : PubMed/NCBI

Chen C, Jiang J, Lü JM, Chai H, Wang X, Lin PH and Yao Q: Resistin descreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 299:H193–H201. 2010. View Article : Google Scholar : PubMed/NCBI

Acquarone E, Monacelli F, Borghi R, Nencioni A and Odetti P: Resistin: A reappraisal. Mech Ageing Dev. 178:46–63. 2019. View Article : Google Scholar : PubMed/NCBI

Iwaki T, Urano T and Umemura K: PAI-1, progress in understanding the clinical problem and its aetiology. Br J Heamatol. 157:291–298. 2012. View Article : Google Scholar

Para I, Albu A and Porojan MD: Adipokines and arterial stiffness in obesity. Medicina (Kaunas). 57:6532021. View Article : Google Scholar : PubMed/NCBI

Mertens I and Van Gaal LF: Obesity, haemostasis and the fibrinolytic system. Obes Rev. 3:85–101. 2002. View Article : Google Scholar : PubMed/NCBI

Juhan-Vague I, Alessi MC, Mavri A and Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 1:1575–1579. 2003. View Article : Google Scholar : PubMed/NCBI

Tschoner A, Sturm W, Engl J, Kaser S, Laimer M, Laimer E, Klaus A, Patsch JR and Ebenbichler CF: Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr Metab Cardiovasc Dis. 22:340–346. 2012. View Article : Google Scholar : PubMed/NCBI

Khoukaz HB, Ji Y, Braet DJ, Vadali M, Abdelhamid AA, Emal CD, Lawrence DA and Fay WP: Drug targeting of plasminogen activator inhibitor-1 inhibits metabolic dysfunction and atherosclerosis in murine model of metabolic syndrome. Arterioscler Thromb Vasc Biol. 40:1479–1490. 2020. View Article : Google Scholar : PubMed/NCBI

Eitzman DT, Westrick RJ, Xu Z, Tyson J and Grinsburg D: Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 96:4212–4215. 2000. View Article : Google Scholar : PubMed/NCBI

Alessi MC and Juhan-Vague I: PAI-1 and the metabolic syndrome: Links, causes and consequences. Arterioscler Thromb Vasc Biol. 16:2200–2207. 2006. View Article : Google Scholar : PubMed/NCBI

Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, et al: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 53:336–346. 2004. View Article : Google Scholar : PubMed/NCBI

Gleeson LE, Sheedy FJ, Palsson-McDermott EM, Triglia D, O'Leary SM, O'Sullivan MP, O'Neill LA and Keane J: Cytting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication. J Immunol. 196:2444–2449. 2016. View Article : Google Scholar : PubMed/NCBI

Shoelson SE, Herrero L and Naaz A: Obesity, inflammation and insulin resistance. Gastroenterology. 132:2169–2180. 2007. View Article : Google Scholar : PubMed/NCBI

Stojsavljević S, Palčić MG, Jukić LV, Duvnjak LS and Duvnjak M: Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 20:18070–18091. 2014. View Article : Google Scholar : PubMed/NCBI

Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR and Pedersen BK: Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 54:2936–2945. 2005. View Article : Google Scholar

Ruan H and Lodish HF: Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 14:447–455. 2003. View Article : Google Scholar : PubMed/NCBI

Illei GG and Lipsky PE: Novel, antigen-specific therapeutic approaches to autoimmuneinflammatory diseses. Curr Opin Immunol. 12:712–718. 2000. View Article : Google Scholar : PubMed/NCBI

Chandel NS, Schumacker PT and Arch RH: Reactive oxygen species are downstream products of TRAF-mediated signal trasduction. J Biol Chem. 276:42728–42736. 2001. View Article : Google Scholar : PubMed/NCBI

Micheau O and Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 114:181–190. 2003. View Article : Google Scholar : PubMed/NCBI

Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes LA, Denys A, Feldmann M, Brennan FM and Foxwell BMJ: A novel mechanism for TNF-alpha regulation by p38 MAPK: Involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol. 173:6928–6937. 2004. View Article : Google Scholar : PubMed/NCBI

Wang B and Trayhurn P: Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch. 452:418–427. 2006. View Article : Google Scholar : PubMed/NCBI

Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA and Apte RN: IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 187:4835–4843. 2011. View Article : Google Scholar : PubMed/NCBI

Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR and Aunins J: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 356:768–774. 1992. View Article : Google Scholar : PubMed/NCBI

Akdis M, Arab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R, et al: Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 138:984–1010. 2016. View Article : Google Scholar : PubMed/NCBI

Ghabari M, Maragheh SM, Aghazadeh A, Mehrjuyan SR, Hussen BM, Shadbad MA, Dastmalchi N and Safaralizadeh R: Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies. Int Immunopharmacol. 96:1077652021. View Article : Google Scholar : PubMed/NCBI

Speaker KJ and Fleshner M: Interleukin-1 beta: A potential link between stress and the development of visceral obesity. BMC Physiol. 12:1–15. 2012. View Article : Google Scholar : PubMed/NCBI

Bruun JM, Pedersen SB, Kristensen K and Richelsen B: Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol. 190:91–99. 2002. View Article : Google Scholar : PubMed/NCBI

Gonzalez RR and Leavis P: Leptin upregulates β3-integrin expression and interleukin-1β upregulates leptin and leptin receptor expression in human endometrial epithelial cell cultures. Endocrine. 16:21–28. 2021. View Article : Google Scholar

Müller G, Ertl J, Gerl M and Preidisch G: Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem. 272:10585–10593. 1997. View Article : Google Scholar : PubMed/NCBI

Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF and Tilg H: Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med. 17:840–845. 2011. View Article : Google Scholar : PubMed/NCBI

Shaul ME, Bennett G, Strissel KJ, Greenberg AS and Obin MS: Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet-induced obesity in mice. Diabetes. 59:1171–1181. 2010. View Article : Google Scholar : PubMed/NCBI

Schoettl T, Fischer IP and Ussar S: Heterogeneity of adipose tissue in development and metabolic function. J Exp Biol. 221 (Pt Suppl 1):jeb1629582018. View Article : Google Scholar : PubMed/NCBI

Buechler C, Krautbauer S and Eisinger K: Adipose tissue fibrosis. World J Diabetes. 6:548–553. 2015. View Article : Google Scholar : PubMed/NCBI

Shikama Y, Aki N, Hata A, Nishimura M, Oyadomari S and Funaki M: Palmitate-stimulated monocytes induce adhesion molecule expression in endothelial cells via IL-1 signaling pathway. J Cell Physiol. 230:732–742. 2015. View Article : Google Scholar : PubMed/NCBI

Miura K, Kodama Y, Inokuchi S, Scnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA and Seki E: Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 139:323–334. 2010. View Article : Google Scholar : PubMed/NCBI

Gao D, Madi M, Ding C, Fok M, Steele T, Ford C, Hunter L and Bing C: Interleukin-1β mediates macrophage-induced impairemnet of insulin signalin in human primary adipocytes. Am J Physiol Endocrinol Metab. 307:E289–E304. 2014. View Article : Google Scholar : PubMed/NCBI

Zhou R, Tardivel A, Thorens B, Choi I and Tschopp J: Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 11:136–140. 2010. View Article : Google Scholar : PubMed/NCBI

Calabrese L, Fiocco Z, Satoh TK, Peris K and French LE: Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases. Br J Dermatol. 186:925–941. 2022. View Article : Google Scholar : PubMed/NCBI

Maedler K, Sergeev P, Ris F, Oberholzer J, Holler-Jemelka H, Spinas GA, Kaiser N, Halban PA and Donath MY: Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 110:851–860. 2002. View Article : Google Scholar : PubMed/NCBI

Wang Q, Zhang H, Zhao B and Fei H: IL-1beta caused pancreatic beta-cells apoptosis is mediated in part by endoplasmic reticulum stress via the induction of endoplasmic reticulum Ca2+ release through the c-Jun N-terminal kinase pathway. Mol Cell Biochem. 324:183–190. 2009. View Article : Google Scholar : PubMed/NCBI

Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG and Hanash SM: An immune response manifested by the common occurrence of annexins I and II aytoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA. 98:9824–9829. 2001. View Article : Google Scholar : PubMed/NCBI

Scheller J, Chalaris A, Schmidt-Arras D and Rose-John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888. 2011. View Article : Google Scholar : PubMed/NCBI

Tanaka T, Narazaki M and Kishimoto T: IL-6 in inflammation, immunity and disease. Cold Spring Harb Perspect Biol. 6:a0162952014. View Article : Google Scholar : PubMed/NCBI

IL6R Genetics Consortium Emerging Risk Factors and Collaboration, . Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, et al: Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. Lancet. 379:1205–1213. 2012. View Article : Google Scholar : PubMed/NCBI

Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A and Bayard F: Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis. 156:315–320. 2001. View Article : Google Scholar : PubMed/NCBI

Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJF, Trautwein C, Luchtefeld M, Schmittkamp C, Heeneman S, et al: Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 110:3493–3500. 2004. View Article : Google Scholar : PubMed/NCBI

Mishra D, Richard JE, Maric I, Porteiro B, Häring M, Kooijman S, Musovic S, Eerola K, López-Ferreras L, Peris E, et al: Parabrachial interleukin-6 reduces body weight and food intake and increases thermogenesis to regulate energy metabolism. Cell Rep. 26:3011–3026. 2019. View Article : Google Scholar : PubMed/NCBI

Rosen ED and Spiegelman BM: What we talk about when we talk about fat. Cell. 156:20–44. 2014. View Article : Google Scholar : PubMed/NCBI

Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S and Coppack SW: Subcutaneous adipose tissue related interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 82:4196–4200. 1997. View Article : Google Scholar : PubMed/NCBI

Sopasakis VR, Sandqvist M, Gustafson B, Hammerstedt A, Schmelz M, Yang X, Jansson PA and Smith U: High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res. 12:454–460. 2004. View Article : Google Scholar : PubMed/NCBI

Fernandez-Real JM and Ricart W: Insulin resistance and chronic cardiovascular inflammatory sundrome. Endocr Rev. 24:278–301. 2003. View Article : Google Scholar : PubMed/NCBI

Charles BA, Doumatey A, Huang H, Zhou J, Chen G, Shriner D, Adeyemo A and Rotimi CN: The roles of IL-6, IL-10 and IL-1RA in obesity and insulin resistance in African-Americans. J Clin Endocrinol Metab. 96:E2018–E2022. 2011. View Article : Google Scholar : PubMed/NCBI

Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS and Chrousos GP: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab. 82:4167–4170. 1997. View Article : Google Scholar : PubMed/NCBI

Pradhan AD, Manson JE, Rifai N, Buring JE and Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 286:327–334. 2001. View Article : Google Scholar : PubMed/NCBI

Bastard JP, Maachi M, van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J and Hainque B: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 87:2084–2089. 2002. View Article : Google Scholar : PubMed/NCBI

Kopp HP, Kopp CW, Festa A, Krzyzanowaska K, Kriwanek S, Minar E, Roka R and Schernthaner G: Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Throm Vasc Biol. 23:1042–1047. 2003. View Article : Google Scholar : PubMed/NCBI

Xu E, Pereira MMA, Karakasilioti I, Theurich S, Al-Maarri M, Rappl G, Waisman A, Wenderlich FT and Brüning JC: Temporal and tissue-specific requirements for T-lympocyte IL-6 signaling in obesity-associated inflammation and insulin resistance. Nat Commun. 8:148032017. View Article : Google Scholar : PubMed/NCBI

Wondmkum YT: Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes. 13:3611–3616. 2020. View Article : Google Scholar : PubMed/NCBI

Fu Z, Gilbert ER and Liu D: Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 9:25–53. 2013. View Article : Google Scholar : PubMed/NCBI

Röder PV, Wu B, Liu Y and Han W: Pancreatic regulation of glucose homeostasis. Exp Mol Med. 48:e2192016. View Article : Google Scholar : PubMed/NCBI

Fazakerley DJ, Krycer JR, Kearney AL, Hocking SL and James DE: Muscle and adipose tissue insulin resistance: Malady without mechanism? J Lipid Res. 60:1720–1732. 2019. View Article : Google Scholar : PubMed/NCBI

Newsholme P and Krause M: Nutritional regulation of insulin secretion: Implications for diabetes. Clin Biochem Rev. 33:35–47. 2012.PubMed/NCBI

Dashty M: A quick look at biochemistry: Carbohydrate metabolism. Clin Biochem. 46:1339–1352. 2013. View Article : Google Scholar : PubMed/NCBI

Samuel VT and Shulman GI: The pathogenesis of insulin resistance: Intergrating signaling pathways and substrate flux. J Clin Invest. 126:12–22. 2016. View Article : Google Scholar : PubMed/NCBI

Taniguchi CM, Emanuelli B and Kahn CR: Critical nodes in signaling pathways: Insights into insulin action. Nat Rev Mol Cell Biol. 7:85–96. 2006. View Article : Google Scholar : PubMed/NCBI

Merry TL, Hedges CP, Masson SW, Laube B, Pöhlmann D, Wueest S, Walsh ME, Arnold M, Langhans W, Konrad D, et al: Partial impairment of insulin receptor expression mimics fasting to prevent diet-induced fatty liver diseasee. Nat Commun. 11:20802020. View Article : Google Scholar : PubMed/NCBI

Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y and Roth J: Insulin resistance and hyperinsulinemia: Is hyperinsulinemia the cart or the horse? Diabetes Car. 31 (Suppl 2):S262–S268. 2008. View Article : Google Scholar : PubMed/NCBI

Braccini L, Ciraolo E, Campa CC, Perino A, Longo DL, Tibolla G, Pregnolato M, Cao Y, Tassone B, Damilano F, et al: PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat Commun. 6:74002015. View Article : Google Scholar : PubMed/NCBI

Huang X, Liu G, Guo J and Su Z: The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 14:1483–1496. 2018. View Article : Google Scholar : PubMed/NCBI

Gray SL, Donald C, Jetha A, Covey SD and Kieffer TJ: Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic beta-cell leptin signaling. Endocrinology. 151:4178–4186. 2010. View Article : Google Scholar : PubMed/NCBI

Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 27:1047–1053. 2004. View Article : Google Scholar : PubMed/NCBI

Smith BW and Adams LA: Nonalcoholic faty liver disease and diabetes mellitus: Pathogenesis and treatment. Nat Rev Endocrinol. 7:456–465. 2011. View Article : Google Scholar : PubMed/NCBI

Willians AJK and Long AE: Following the fate of the failing β-cell: New insights from first-phase insulin responses. Diabetes. 62:3990–3992. 2013. View Article : Google Scholar

Gariani K, Philippe J and Jornayvaz FR: Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside. Diabetes Metab. 39:16–26. 2013. View Article : Google Scholar : PubMed/NCBI

Zhao J, Wu Y, Rong X, Zheng C and Guo J: Anti-lipolysis induced by insulin in diverse pathophysiologic conditions of adipose tissue. Diabetes Metab Syndr Obes. 13:1575–1585. 2020. View Article : Google Scholar : PubMed/NCBI

Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF and Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 48:1270–1274. 1999. View Article : Google Scholar : PubMed/NCBI

Boden G and Shulman GI: Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 32:14–23. 2002. View Article : Google Scholar : PubMed/NCBI

Unger RH and Zhou YT: Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 50 (Suppl 1):S118–S121. 2001. View Article : Google Scholar : PubMed/NCBI

Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferranini E and Rizzetto M: Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabeltologia. 48:634–642. 2005. View Article : Google Scholar

Perry RJ, Samuel VT, Petersen KF and Shulman GI: The role of hepatic insulin resistance and type 2 diabetes. Nature. 510:84–91. 2014. View Article : Google Scholar : PubMed/NCBI

Brown MS and Goldstein JL: Selective versus total insulin resistance: A pathogenic paradox. Cell Metab. 7:95–96. 2008. View Article : Google Scholar : PubMed/NCBI

Kim GT, Kim SJ, Park SH, Lee D and Park TS: Hepatic expression of the serine palmitoyltansferase subunit Sptlc2 reduces lipid droplets in the liver by activating VLDL secretion. J Lipid Atheroscler. 9:291–303. 2020. View Article : Google Scholar : PubMed/NCBI

Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G and Stec DE: Obesity-induced hypertension: Role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 285:17271–17276. 2010. View Article : Google Scholar : PubMed/NCBI

Weickert MO and Pfeiffer AFH: Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia. 4:1732–1741. 2006. View Article : Google Scholar : PubMed/NCBI

Murakami T, Michelagnoli S, Longhi R, Gianfranceschi G, Pazzucconi F, Calabresi L, Sirtori CR and Franceschini G: Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 15:1819–1828. 1995. View Article : Google Scholar : PubMed/NCBI

Eisenberg S, Gavish D, Oschry Y, Fainaru M and Deckelbaum RJ: Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest. 74:470–482. 1984. View Article : Google Scholar : PubMed/NCBI

Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A and Dandona P: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 52:2882–2887. 2003. View Article : Google Scholar : PubMed/NCBI

Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J and Lambert G: Sympathetic nervous system and insulin resistance from obesity to diabetes. Am J Hypertens. 14((11 Pt 2)): 304S–309S. 2001. View Article : Google Scholar : PubMed/NCBI

Samad F and Ruf W: Inflammation, obesity and thrombosis. Blood. 122:3415–3422. 2013. View Article : Google Scholar : PubMed/NCBI

Ernst E and Resch KL: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med. 118:956–963. 1993. View Article : Google Scholar : PubMed/NCBI

Kannel WB, Wolf PA, Castelli WP and D'Agostino RB: Fibrionogen and risk of cardiovascular disease. The Framingham study. JAMA. 258:1183–1186. 1987. View Article : Google Scholar : PubMed/NCBI

Nieuwdorp M, Stroes ES, Meijers JC and Buller H: Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol. 5:155–159. 2005. View Article : Google Scholar : PubMed/NCBI

Raynaud E, Perez-Martin A, Brun JF, Aïssa-Benhaddad A, Fédou C and Mercier J: Atherosclerosis. 150:365–370. 2000. View Article : Google Scholar : PubMed/NCBI

Tabrez S, Jabir NR, Shakil S and Alama MN: Association of plasma fibrinogen level with insulin resistance in angiographically confirmed coronary artery disease patients. Crit Rev Eukaryot Gene Expr. 29:277–285. 2019. View Article : Google Scholar : PubMed/NCBI

Bryk-Wiązania AH and Undas A: Hypofribrinolysis in type 2 diabetes and its clinical implications: From mechanisms to pharmacological modulation. Cardiovasc Diabetol. 20:1912021. View Article : Google Scholar : PubMed/NCBI

Davalos D and Akassoglou K: Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 34:43–62. 2012. View Article : Google Scholar : PubMed/NCBI

Nawaz SS and Siddiqui K: Plasminogen activator inhibitor-1 mediated downregulation of adiponectin in type 2 diabetic patients with metabolic syndrome. Cytokine X. 4:1000642002. View Article : Google Scholar : PubMed/NCBI

Chen R, Yan J, Liu P, Wang Z and Wang C: Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke. Metab Brain Dis. 32:667–673. 2017. View Article : Google Scholar : PubMed/NCBI

Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett. 580:2917–2921. 2006. View Article : Google Scholar : PubMed/NCBI

Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruge JB and Gaal LFV: Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. Thromb Haemost. 94:1190–1195. 2005. View Article : Google Scholar : PubMed/NCBI

Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura N, Fukuda Y, Takemura K, et al: Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med. 2:800–803. 1996. View Article : Google Scholar : PubMed/NCBI

Kaji H: Adipose tissue-derived plasminogen activator inhibitor-1 function and regulation. Compr Physiol. 6:1873–1896. 2016. View Article : Google Scholar : PubMed/NCBI

Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1595–1607. 1988. View Article : Google Scholar : PubMed/NCBI

Alberti KG, Zimmet P and Shaw J; IDF Edipemiology Task Force Consensus Group, : The metabolic syndrome-a new world-wide definition. Lancet. 366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI

Zafar U, Khaliq S, Ahmad HU, Manzoor S and Lone KP: Metabolic syndrome: An update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens). 17:299–313. 2018. View Article : Google Scholar : PubMed/NCBI

Spiegelman BM and Flier JS: Obesity and the regulation of energy balance. Cell. 104:531–543. 2001. View Article : Google Scholar : PubMed/NCBI

Mottilo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL and Eisenberg MJ: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 56:1113–1132. 2010. View Article : Google Scholar

Weiss R, Bremer AA and Lusting RH: What is metabolic syndrome, and why are children getting it? Ann N Y Acad Sci. 1281:123–140. 2013. View Article : Google Scholar : PubMed/NCBI

Grundy SM: Metabolic syndrome pandemic. Arteroscler Thromb Vasc Biol. 28:629–636. 2008. View Article : Google Scholar : PubMed/NCBI

Ford ES, Li C and Zhao G: Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2:180–193. 2010. View Article : Google Scholar : PubMed/NCBI

Kahn R, Buse J, Ferrannini E and Stern M: The metabolic syndrome: Time for a critical appraisal. Joint statement from the Americal diabetes association and the European association for the study of diabetes. Diabetologia. 48:1684–1699. 2005. View Article : Google Scholar : PubMed/NCBI

Pi-Sunyer X: The metabolic syndrome: How to approach differing definitions. Med Clin North Am. 91:1025–1040. 2007. View Article : Google Scholar : PubMed/NCBI

Chung G, Jung HS and Kim HJ: Sociodemographic and health characteristics associated with metabolic syndrome in men and women aged ≥50 Years. Metab Sundr Relat Disord. 19:159–166. 2021. View Article : Google Scholar : PubMed/NCBI

Hydrie MZ, Shera AS, Fawwad A, Basit A and Hussain A: Prevalence of metabolic syndrome in urban Pakistan (Karachi): Comparison of newly proposed international diabetes federation and modified adult treatment panel III criteria. Metab Syndr Relat Disord. 7:119–124. 2009. View Article : Google Scholar : PubMed/NCBI

Rosenbaum M, Sy M, Pavlovich K, Leibel RL and Hirsch J: Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest. 118:2583–2591. 2008.PubMed/NCBI

Imai SI: Nicotinamide phosphoribosyltrasferase (Nampt): A link between NED biology, metabolism, and disease. Curr Pharm Des. 15:20–28. 2009. View Article : Google Scholar : PubMed/NCBI

Lago F, Dieguez C, Gomez-Reino G and Gulillo O: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 3:716–724. 2007. View Article : Google Scholar : PubMed/NCBI

Hopps E, Noto D, Caimi G and Averna MR: A novel comoponent of the metabolic syndrome: The oxidative stress. Nutr Metab Cardiovasc Dis. 20:72–77. 2010. View Article : Google Scholar : PubMed/NCBI

Vona R, Gambardella L, Cittadini C, Straface E and Pietraforte D: Biomarkers of oxidative stress in metabolic syndrome and associated dieseases. Oxid Med Cell Longev. 2019:82672342019. View Article : Google Scholar : PubMed/NCBI

Schieber M and Chandel NS: ROS function in redox signaling and oxidative stress. Curr Biol. 24:R453–R462. 2014. View Article : Google Scholar : PubMed/NCBI

Juan CA, de la Lastra JM, Plou FJ and Pérez-Lebeña EP: The chemistry of reactive oxygen species (ROS) revisited: Outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int J Mol Sci. 22:46422021. View Article : Google Scholar : PubMed/NCBI

Grattagliano I, Palmieri VO, Portincasa P, Moschetta A and Palasciano G: Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hypothesis. J Nutr Biochem. 19:491–504. 2008. View Article : Google Scholar : PubMed/NCBI

Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, Durante-Montiel I, Sánchez-Rivera G, Valadez-Vega C and Morales-González JA: Inflammation, oxidative stress, and obesity. Int J Mol Sci. 12:3117–3132. 2001. View Article : Google Scholar : PubMed/NCBI

Sena CM, Leadro A, Azul L, Seiça R and Perry G: Vascular oxidative stress: Impact and therapeutic approaches. Front Physiol. 9:16682018. View Article : Google Scholar : PubMed/NCBI

Smirne C, Croce E, Di Benedetoo D, Cantaluppi V, Comi C, Sainaghi PP, Minisini R, Grossini E and Pirisi M: Oxidative stress in non-alchoholic fatty liver disease. Livers. 2:30–76. 2022. View Article : Google Scholar

Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E and Golditz GA: Imact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 161:1581–1586. 2001. View Article : Google Scholar : PubMed/NCBI

Rother KI: Diabetes treatment-Bridging the devide. N Engl J Med. 356:1499–1501. 2007. View Article : Google Scholar : PubMed/NCBI

Norhammar A and Schenck-Gustafsson K: Type 2 diabetes and cardiovascular disease in women. Diabetologia. 56:1–9. 2013. View Article : Google Scholar : PubMed/NCBI

Chan JM, Rimm EB, Colditz GA, Stampfer MJ and Willett WC: Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 17:961–969. 1994. View Article : Google Scholar : PubMed/NCBI

Colditz GA, Willett WC, Rotnitzky A and Manson JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 122:481–486. 1995. View Article : Google Scholar : PubMed/NCBI

Wannamethee SG and Shaper AG: Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care. 22:1266–1272. 1999. View Article : Google Scholar : PubMed/NCBI

Schienkiewitz A, Schulz MB, Hoffmann K, Kroke A and Boeing H: Body mass index history and risk of type 2 diabetes: Results from the European Prospective Investigation into cancer nutrition (EPIC)-Potsdam study. Am J Clin Nutr. 84:427–433. 2006. View Article : Google Scholar : PubMed/NCBI

DeFronzo RA: Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 88:787–835. 2004. View Article : Google Scholar : PubMed/NCBI

Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A and DeFronzo RA: Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis. J Clin Endocrinol Metab. 90:493–500. 2005. View Article : Google Scholar : PubMed/NCBI

Panenin F, Castantino S and Cosentino F: Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep. 16:4192014. View Article : Google Scholar : PubMed/NCBI

Abdul-Ghami MA and DeFronzo RA: Phathophysiology of prediabetes. Curr Diab Rep. 9:193–199. 2009. View Article : Google Scholar : PubMed/NCBI

Reaven GM: Insulin resistance: The link between obesity and cardiovascular disease. Med Clin North Am. 95:875–892. 2011. View Article : Google Scholar : PubMed/NCBI

DeFronzo RA, Ferrannini E and Simonson DC: Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 38:387–395. 1989. View Article : Google Scholar : PubMed/NCBI

Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA and Shulman RG: Quatitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 322:223–228. 1990. View Article : Google Scholar : PubMed/NCBI

McGarry JD: Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 51:7–18. 2002. View Article : Google Scholar : PubMed/NCBI

Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Madarino L, DeFronzo R and Cusi K: A substained increase in plasma free fatty acids impairs insulin secretion in nondiabetic sujects genetically predisposed to develop type 2 diabetes. Diabetes. 52:2461–2474. 2003. View Article : Google Scholar : PubMed/NCBI

Lei XG and Vatamaniuk MZ: Two tales of antioxidant enzymes on β cells and diabetes. Antioxid Redox Signal. 14:489–503. 2011. View Article : Google Scholar : PubMed/NCBI

Krebs M, Krssaak M, Bernroider E, Anderwald C, Brehm A, Meyerspeer M, Nowotny P, Roth E, Waldhäusl W and Roden M: Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes. 51:599–605. 2002. View Article : Google Scholar : PubMed/NCBI

Pi-Sunyer FX: The epidemiology of central fat distribution in relation to disease. Nutr Rev. 62((7 Pt2)): S120–S126. 2004. View Article : Google Scholar : PubMed/NCBI

Despres JP: Intra-abdominal obesity: An untreated risk factor for type 2 diabetes and cardiovascular disease. J Endocrinol Invest. 29 (3 Suppl):S77–S82. 2006.

Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nomas C and Kahn R; Association for Weight Management and Obesity Prevention; NASSO, the Obesity Society; American Society for Nutrition, : American Diabetes Association: Waist circumference and cardiometabolic risk: A consensus statement from shaping America's health: Association for weight management and obesity pevention; NAASO, the obesity society; the American society for nutrition; and the American diabetes association. Diabetes Care. 30:1647–1652. 2007. View Article : Google Scholar : PubMed/NCBI

Ashwell M, Gumn P and Gibson S: Waist-to-height is a better screening tool than waist cincumference and BMI for adult cardiometabolic risk factors: Systemic review and meta-analysis. Obes Rev. 13:275–286. 2012. View Article : Google Scholar : PubMed/NCBI

Kouli GM, Panagiotakos DB, Kyrou I, Georgousopoulou EN, Chryoshoou C, Tsigos C, Tousoulis D and Pitsavos C: Visceral adiposity index and 10-year cardiovascular disease incidence. The ATTICA study. Nutr Metab Cardiovasc Dis. 27:881–889. 2017. View Article : Google Scholar : PubMed/NCBI

Weiss R: Fat distribution and storage: How much, where, and how? Eur J Endocrinol. 157 (Suppl 1):S39–S45. 2007. View Article : Google Scholar : PubMed/NCBI

Montague CT and O'Rahilly S: The perils of portliness: Causes and consequences of viscelar adiposity. Diabetes. 49:883–888. 2000. View Article : Google Scholar : PubMed/NCBI

Yang X and Smith U: Adipose tissue distribution and risk of metabolic disease: Does thiazolidinedione-induced adipose tissue redistribution provide a clue to the anwer? Diagetologia. 50:1127–1139. 2007. View Article : Google Scholar : PubMed/NCBI

Peraldi P and Spiegelman B: TNF-α and insulin resistance: Summary and future prospects. Mol Cell Biochem. 182:169–175. 1998. View Article : Google Scholar : PubMed/NCBI

Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 27:813–823. 2004. View Article : Google Scholar : PubMed/NCBI

Han CY: Roles of reactive oxygen species on insulin resistance in adipose tissue. Diabetes Metab J. 40:272–279. 2016. View Article : Google Scholar : PubMed/NCBI

Yan LJ: Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med. 1:7–13. 2018. View Article : Google Scholar : PubMed/NCBI

Dutta BJ, Singh S, Seksaria S, Gupta GD and Singh A: Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies. Pharmacol Res. 182:1063582022. View Article : Google Scholar : PubMed/NCBI

Li H, Ren J, Li Y, Wu Q and Wei J: Oxidative stress: The nexus of obesity and cognitive dysfunction in diabetes. Front Endocrinol (Lausanne). 14:11340252023. View Article : Google Scholar : PubMed/NCBI

Emanuela F, Grazia M, Marco DR, Paola LM, Giorgio F and Marco B: Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab. 2012:4763802012. View Article : Google Scholar : PubMed/NCBI

Böni-Schnetzler M and Meier DT: Islet inflammation in type 2 diabetes. Semin Immunopathol. 41:501–513. 2019. View Article : Google Scholar : PubMed/NCBI

Larsen CN, Faulenbach A, Vaag Α, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T and Donath MY: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 356:1517–1526. 2007. View Article : Google Scholar : PubMed/NCBI

Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY and Mandrup-Poulsen T: Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 32:1663–1668. 2009. View Article : Google Scholar : PubMed/NCBI

Infante M, Padilla N, Alejandro R, Caprio M, Della-Morte D, Fabbri A and Ricordi C: Diabetes-modifying antirheumatic drugs: The roles of DMARDs as glucose-lowering agents. Medicina (Kaunas). 58:5712022. View Article : Google Scholar : PubMed/NCBI

Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK III, Skerra A and Dinarell CA: PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. J Biol Chem. 295:868–882. 2020. View Article : Google Scholar : PubMed/NCBI

Tegtmeyer K, Atassi G, Zhao J, Maloney NJ and Lio PA: Off-Label studies on anakinra in dermatology: A review. J Dermatolog Treat. 33:73–86. 2022. View Article : Google Scholar : PubMed/NCBI

van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG and Tack CJ: Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 96:2119–2126. 2011. View Article : Google Scholar : PubMed/NCBI

van Poppel PCM, van Asseldonk EJP, Holst JJ, Vilsbøll T, Netea MG and Tack CJ: The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 16:1269–1273. 2014. View Article : Google Scholar : PubMed/NCBI

Cucak H, Hansen G, Vrang N, Skarsfeldt T, Steiness E and Jelsing J: The IL-1β receptor antagonist SER140 postpones the onset of diabetes in female nonobese diabetic mice. J Diabetes Res. 2016:74846012016. View Article : Google Scholar : PubMed/NCBI

Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, Solinger AM, Mandrup-Poulsen T, Dinarello CA and Donath MY: Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 35:1654–1662. 2012. View Article : Google Scholar : PubMed/NCBI

Rissanen A, Howard CP, Botha J and Thuren T; Global Investigators, : Effects of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: Results of a randomized placebo-controlled trial. Diabetes Obes Metab. 14:1088–1096. 2012. View Article : Google Scholar : PubMed/NCBI

Hensen J, Howard CP, Walter V and Thuren T: Impact of interleukin-1β antibody (canakinumab) on glycemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 39:524–531. 2013. View Article : Google Scholar : PubMed/NCBI

Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J and Thuren T; on the behalf of CANTOS Pilot Investigative Group, : Effects of Interleukin-1β Inhibition with Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial. Circulation. 126:2739–2748. 2012. View Article : Google Scholar : PubMed/NCBI

Choudhury RP, Birks JS, Manii V, Biasiolli L, Robson MD, L'Allier PL, Gingras MA, Alie N, McLaughlin MA, Basson CT, et al: Artherial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol. 68:1769–1780. 2016. View Article : Google Scholar : PubMed/NCBI

Noe A, Howard C, Thuren T, Taylor A and Skerjanec A: Pharmacokinetic and pharmacodynamics characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus. Clin Ther. 36:1625–1637. 2014. View Article : Google Scholar : PubMed/NCBI

Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Schere JC, De Gaetano A, Berg JK and Landschulz WH: Double blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1 antibody, in patients with type 2 diabetes. Diabetes Care. 36:2239–2246. 2013. View Article : Google Scholar : PubMed/NCBI

Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P and Ridker PM: Anti-inflimmatory therapy with canakinumad for the prevention and management of diabetes. J Am Coll Cardiol. 71:2392–2401. 2018. View Article : Google Scholar : PubMed/NCBI

Olson NC, Callas PW, Hanley AJG, Festa A, Haffner SM, Wagenknecht LE and Tracy RP: Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: The insulin resistance atherosclerosis study. J Clin Endocrinol Metab. 97:1032–1040. 2012. View Article : Google Scholar : PubMed/NCBI

Wascher TC, Lindeman JHN, Sourij H, Kooistra T, Pacini G and Roden M: Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in ‘healthy’ men with metabolic syndrome. Mol Med. 17:189–193. 2011. View Article : Google Scholar : PubMed/NCBI

van den Oever IAM, Baniaamam M, Simsek S, Raterman HG, van Denderen JC, van Eijk IC, Peters MJL, van der Horst-Bruinsma IE, Smulders YM and Nurmohamed MT: The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatol Int. 41:319–328. 2021. View Article : Google Scholar : PubMed/NCBI

Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN and Drosos AA: Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 64:765–766. 2005. View Article : Google Scholar : PubMed/NCBI

Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua G, Sanchez-Andrade A, Martin J and Llorca J: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 24:83–86. 2006.PubMed/NCBI

Haida KS, Bertachini G, Tavoni T, Guilhermetti M, Loures MR and Bazotte RB: Infliximab treatment prevents hyperglycemia and the intensification of hepatic gluconeogenesis in an animal model of high fat diet-induced liver glucose overproduction. Braz Arch Biol Technol. 55:389–393. 2012. View Article : Google Scholar

Méndez-García LA, Trejo-Millán F, Martínez-Reyes CP, Majarrez-Reyna AN, Esquivel-Velázquez M, Melendez-Mier G, Islas-Andrade S, Rojas-Bernbé A, Kzhyshkowska J and Escobedo G: Infliximab ameriorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scan J Immunol. 88:e127162018. View Article : Google Scholar : PubMed/NCBI

Abdelhamid YA, Elyamany MF, Al-Shorbagy MY and Badary OA: Effects of TNF-α antagonist infliximad on fructose-induced metabolic syndrome in rats. Hum Exp Toxicol. 40:801–811. 2021. View Article : Google Scholar : PubMed/NCBI

Bernstein LE, Berry J, Kim S, Canavan B and Grinspoon SK: Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 166:902–908. 2006. View Article : Google Scholar : PubMed/NCBI

Lo J, Bernstein LE, Canavan B, Torriani M, Jackson MB, Ahima RS and Grinspoon SK: Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metabol. 293:E102–E109. 2007. View Article : Google Scholar : PubMed/NCBI

Bravo C, Cataldo LR, Galgani J, Parada J and Santos JL: Leptin/Adiponectin ratios using either total or high molecular weight adiponectin as biomarkers of systemic insulin sensitivity in normoglycemic women. Diabetes Res. 2017:90310792017.PubMed/NCBI

Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, Khor VK, Ahima RS and Grinspoon SK: TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 96:E146–E150. 2011. View Article : Google Scholar : PubMed/NCBI

Paquot N, Castillo MJ, Lefèbvre PJ and Scheen AJ: No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab. 85:1316–1319. 2000. View Article : Google Scholar : PubMed/NCBI

Dominguez H, Storgaard H, Rask-Madsen C, Hermann TS, Ihlemann N, Nielsen DB, Spohr C, Kober L, Vaag A and Torp-Pedersen C: Metabolic and vascular effects of tumor necrosis factor-α blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 42:517–525. 2005. View Article : Google Scholar : PubMed/NCBI

Ronti T, Lupattelli G and Mannarino E: The endocrine function of adipose tissue: An update. Clin Endocrinol (Oxf). 64:355–365. 2006. View Article : Google Scholar : PubMed/NCBI

Hu D, Russell RD, Remash D, Greenaway T, Rattigan S, Squibb KA, Jones G, Ross RM, Roberts CK, Premilovac D, et al: Are the metabolic benefits of resistance in type 2 diabetes linked to improvement in adipose tissue microvascular blood flow? Am J Physiol Endocrinol Metab. 315:E1242–E1250. 2018. View Article : Google Scholar : PubMed/NCBI

Ruscitti P, Berardicurti O, Cipriani P and Giacomelli R; TRACK Study Group, : Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: Long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomized, controlled trial. Clin Exp Rheumatol. 39:403–406. 2021. View Article : Google Scholar : PubMed/NCBI

Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Gonzalez-Lopez R and Santiago-Hernandez NJ: Effect of diacerein on insulin secretion and metabolic control in drug-naïve patients with type 2 diabetes. Diabetes Care. 34:1591–1594. 2011. View Article : Google Scholar : PubMed/NCBI

Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB and Salles GF: Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Care. 40:1356–1363. 2017. View Article : Google Scholar : PubMed/NCBI

Tres GS, Fuchs SC, Piovesan F, Koehler-Santos P, Pereira FD, Camey S, Lisboa HK and Moreira LB: Effect of diacerein on metabolic control and inflammatory markers in patients with type 2 diabetes using antidiabetic agents: A randomized controlled trial. J Diabetes Res. 2018:42465212018. View Article : Google Scholar : PubMed/NCBI

Jangsiripornpakorn J, Srisuk S, Chailurkit L, Nimitphong H, Saetung S and Ongphiphadhanakul B: The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncontrolled diabetes. BMC Res Notes. 15:912022. View Article : Google Scholar : PubMed/NCBI

Piovesan F, Tres GS, Moreira LB, Andrades ME, Lisboa HK and Fucks SC: Effects of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: A randomized controlled trial. PLoS One. 12:e01865542017. View Article : Google Scholar : PubMed/NCBI

Di Prospero NA, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L and Rothenberg P: CCR2 antagonism in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Diabetes Obes Metab. 16:1055–1064. 2014. View Article : Google Scholar : PubMed/NCBI

Mulder P, van den Hoek AM and Kleemann R: The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and non-alcoholic steatohepatitis. PLoS One. 12:e01697402017. View Article : Google Scholar : PubMed/NCBI

Huh JH, Kim HM, Lee ES, Kwon MH, Lee BR, Ko HJ and Chung CH: Dual CCR2/5 antagonist attenuates obesity-induced insulin resistance by regulating macrophage recruitment and M1/M2 status. Obesity (Silver Spring). 26:378–386. 2018. View Article : Google Scholar : PubMed/NCBI

Tuttle KR, Brosius FC III, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, et al: JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: Results from a phase 2 randomized controlled clinical trial. Nephrol Dial Transplant. 33:1950–1959. 2018. View Article : Google Scholar : PubMed/NCBI

Faghihimani E, Amnorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F and Amini M: Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 50:537–543. 2013. View Article : Google Scholar : PubMed/NCBI

Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA and Steven E; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team, : Salicylate (Salsalate) in patients with type 2 diabetes: A randomized trial. Ann Intern Med. 159:1–12. 2013. View Article : Google Scholar : PubMed/NCBI

Li D, Zhong J, Zhang Q and Zhang J: Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus. Front Immunol. 14:11251162023. View Article : Google Scholar : PubMed/NCBI

Raimondo MG, Biggioggero M, Crotti C, Becciolini A and Favalli EG: Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Design Dev Ther. 11:1593–1603. 2017. View Article : Google Scholar : PubMed/NCBI

Klinder A, Waletzko-Hellwig J, Sellin ML, Seyfarth-Sehlke A, Wolfien M, Prehn F, Bader R and Jonitz-Heincke A: Effects of the interleukin-6 receptor blocker sarilumab on metabolic activity and differentiation capacity of primary human osteoblasts. Pharmaceutics. 14:13902022. View Article : Google Scholar : PubMed/NCBI

Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GT, González-Gay MA, Mandrup-Poulsen T and Fleischmann R: Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: Post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 22:2062020. View Article : Google Scholar : PubMed/NCBI

Drutskaya MS, Efimou GA, Kruglou AA and Nedospasou SA: Can we design a better anti-cytokine therapy? Semin Arthritis and Rhematism. 49:S39–S42. 2019.PubMed/NCBI

Nosenko MA, Atretkhany KSN, Mokhonov VV, Vasilenko EA, Kruglov AA, Tillib SV, Drutskaya MS and Nedospasov SA: Moduatation of bioavailability of proinflammatory cytokines produced by myeloid cells. Semin Arthritis Rheum. 49:S39–S42. 2019. View Article : Google Scholar : PubMed/NCBI

Velikova TV, Kabakchieva PP, Assyov YS and Georgiev TA: Targeting inflammatory cytokines to improve type 2 diabetes control. Biomed Res Int. 2021:72974192021. View Article : Google Scholar : PubMed/NCBI

Achari A and Jain SK: Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 18:13212017. View Article : Google Scholar : PubMed/NCBI

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka T, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7:941–946. 2001. View Article : Google Scholar : PubMed/NCBI

Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, et al: Induction of adipocyte complement-related protein of 30 kilodaltons by PPRgamma agonists: A potential mechanism of insulin sensitization. Endocrinology. 143:998–1007. 2002. View Article : Google Scholar : PubMed/NCBI

Kolak M, Yki-Järvinen H, Kannisto K, Tiikkainen M, Hamsten A, Eriksson P and Fisher RM: Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab. 92:720–724. 2007. View Article : Google Scholar : PubMed/NCBI

Peraldi P, Xu M and Spiegelman BM: Thiazolidinediones block tumor necrosis factor-alpha-incuded inhibition of insulin signaling. J Clin Invest. 100:1863–1869. 1997. View Article : Google Scholar : PubMed/NCBI

Wolf AM, Wolf D, Rumpold H, Enrich B and Tilg H: Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 323:630–635. 2004. View Article : Google Scholar : PubMed/NCBI

Mosser DM and Zhang X: Interleukin-10: New perspectives on an old cytokine. Immunol Rev. 226:205–218. 2008. View Article : Google Scholar : PubMed/NCBI

Maclsaac RJ and Jerum G: Clinical indications for thiazolidinediones. Aust Prescr. 27:70–74. 2004. View Article : Google Scholar

Quinn CE, Hamilton PK, Lockhart CJ and McVeigh GE: Thiazolidinediones: Effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 153:636–645. 2008. View Article : Google Scholar : PubMed/NCBI

Graham DJ, Green L, Senior JR and Nourjah P: Troglitazone-induced liver failure: A case study. Am J Med. 114:299–306. 2003. View Article : Google Scholar : PubMed/NCBI

Tuccori M, Filion KB, Yin H, Yu OH, Platt RW and Azoulay L: Pioglitazone use and risk of bladder cancer: Population based cohort study. BMJ. 352:i15412016. View Article : Google Scholar : PubMed/NCBI

Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL and Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care. 23:1605–1611. 2000. View Article : Google Scholar : PubMed/NCBI

Mudaliar S, Chang AR and Henry RR: Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications. Endocr Pract. 9:406–416. 2003. View Article : Google Scholar : PubMed/NCBI

Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS and Kosiborod M: Understanding contemporary use of thiazolidinediones. Cir Heart Fail. 12:e0058552019. View Article : Google Scholar : PubMed/NCBI

Ferris FL III and Patz A: Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 28:452–461. 1984. View Article : Google Scholar : PubMed/NCBI

Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S and Williams DF: Diabetic macular edema associated with glitazone use. Retina. 26:562–570. 2006. View Article : Google Scholar : PubMed/NCBI

Vestergaard P: Discrepacies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 18:427–444. 2007. View Article : Google Scholar : PubMed/NCBI

Fonseca V: Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 115:42–48. 2003. View Article : Google Scholar

Ko KD, Kim KK and Lee KR: Does weight gain associated with thiazolidinedione use negatively affect cardiometabolic health? J Obes Metab Syndr. 26:102–106. 2017. View Article : Google Scholar : PubMed/NCBI